Atrial fibrillation (AF) is a major public health burden worldwide, and its prevalence is set to
increase owing to widespread population ageing, especially in rapidly developing countries …

Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have
become available as an alternative to warfarin anticoagulation in non‐valvular atrial …

The aim of this updated statement is to provide comprehensive and timely evidence-based
recommendations on the prevention of stroke among individuals who have not previously …

Background: The global ROCKET AF study evaluated once-daily rivaroxaban vs. warfarin for
stroke and systemic embolism prevention in patients with atrial fibrillation (AF). A separate …

Background: Prasugrel is an antiplatelet agent that shows more prompt, potent, and
consistent platelet inhibition than clopidogrel. The objective of this study was to confirm the …

Background and Purpose—Intracranial hemorrhage rates are higher in Asians than non-
Asians, especially in patients receiving warfarin. This randomized evaluation of long-term …

Despite relatively lower prevalence of atrial fibrillation (AF) in Asians (~ 1%) than in
Caucasians (~ 2%), Asia has a much higher overall disease burden because of its …

Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …

Background: Target anticoagulation levels for warfarin in Japanese patients with non-
valvular atrial fibrillation (NVAF) are unclear. Methods and Results: Of 7,527 patients with …

Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific
Consensus Group Page 1 Address for correspondence: Eun-Seok Shin, MD, PhD, Division of …